Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249728 | 0.86 | PARP1 (0.62) | PARP1 | |
| SCHEMBL1251306 | 0.85 | ACHE (0.50) | CHRM4ACHEBCHE | |
| SCHEMBL1251309 | 0.84 | ACHE (0.49) | CHRM4ACHEBCHE | |
| SCHEMBL1252660 | 0.79 | PARP1 (0.51) | PARP1 | |
| SCHEMBL1251488 | 0.78 | PARP1 (0.55) | PARP1 | |
| SCHEMBL1252095 | 0.77 | PARP1 (0.63) | PARP1 | |
| SCHEMBL1252447 | 0.75 | PARP1 (0.52) | PARP1 | |
| SCHEMBL1252462 | 0.74 | PARP1 (0.48) | PARP1 | |
| SCHEMBL1249810 | 0.74 | PARP1 (0.68) | PARP1 | |
| SCHEMBL1251301 | 0.74 | PARP1 (0.54) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2281818-A1 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1477175-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | MUSK, RNASE1, DPYD | PARP1 4/4885CHRM4 4145/4885ACHE 63/4885 |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | MUSK, RNASE1, DPYD | PARP1 4/4885CHRM4 4164/4885ACHE 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.